COX-2: A target for colon cancer prevention

被引：256
|
作者：
Marnett, LJ
DuBois, RN
机构：
[1] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Biochem, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Chem, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Med, Nashville, TN 37232 USA
[4] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Cell Biol, Nashville, TN 37232 USA
[5] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA
来源：
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY | 2002年 / 42卷
关键词：
cyclooxygenase; prostaglandins; NSAIDs; cancer; prevention;
D O I：
10.1146/annurev.pharmtox.42.082301.164620
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Disease prevention is one area that both public and governmental agencies strongly support owing to its potential for an improved lifestyle and a reduction in health care costs. In this review, we focus on the clinical development of one target for cancer prevention, the COX-2 enzyme. This provides an excellent example of how basic research in biochemistry and pharmacology can lead to translational studies and eventually to approval of a drug by the FDA for use as a chemopreventive agent in humans. It is hoped that, as the genome sequence: is understood more clearly, other targets will emerge that will provide even more effective drugs for future cancer prevention.
引用
收藏
页码：55 / +
页数：26
相关论文
共 50 条
  • [41] Vegetarian fecal water inhibits COX-2 in colon cancer cells
    Petersson, J.
    Huss, U.
    Karlsson, P. C.
    Choi, Y. H.
    Verpoorte, R.
    Rafter, J. J.
    Bohlin, L.
    PLANTA MEDICA, 2008, 74 (09) : 1182 - 1182
  • [42] COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib
    Grösch, S
    Tegeder, I
    Niederberger, E
    Bräutigam, L
    Geisslinger, G
    FASEB JOURNAL, 2001, 15 (12): : 2742 - +
  • [43] Colon polyposis model and COX-2 inhibitors
    Taketo, M
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (11) : 1367S - 1368S
  • [44] Selective COX-2 inhibitors: Potential for cancer prevention and therapy.
    DuBois, RN
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3818S - 3819S
  • [45] Current application of selective COX-2 inhibitors in cancer prevention and treatment
    Stratton, MS
    Alberts, DS
    ONCOLOGY-NEW YORK, 2002, 16 (05): : 37 - 51
  • [46] Prevention of colorectal cancer through the use of COX-2 selective inhibitors
    Richard M. Peek
    Cancer Chemotherapy and Pharmacology, 2004, 54 : S50 - S56
  • [47] Prevention of colorectal cancer through the use of COX-2 selective inhibitors
    Peek, RM
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (Suppl 1) : S50 - S56
  • [48] COX-2 and colorectal cancer
    Ferrández, A
    Prescott, S
    Burt, RW
    CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (27) : 2229 - 2251
  • [49] Tristetraprolin Downregulates the Expression of Both VEGF and COX-2 in Human Colon Cancer
    Cha, Hee Jeong
    Lee, Hyun Hee
    Chae, Seoung Wan
    Cho, Wha Ja
    Kim, Young Min
    Choi, Hye-Jeong
    Choi, Dae Hwa
    Jung, Seok Won
    Min, Young Joo
    Lee, Byung Ju
    Park, Soon Eun
    Park, Jeong Woo
    HEPATO-GASTROENTEROLOGY, 2011, 58 (107) : 790 - 795
  • [50] iNOS, COX-2, and ODC: Regulators of cellular signaling in colon cancer.
    Reddy, BS
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2002, 11 (10) : 1256S - 1257S
12345